HomeCompareKRYAY vs ABBV

KRYAY vs ABBV: Dividend Comparison 2026

KRYAY yields 1.69% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KRYAY wins by $24.0K in total portfolio value· pulled ahead in Year 10
10 years
KRYAY
KRYAY
● Live price
1.69%
Share price
$79.47
Annual div
$1.34
5Y div CAGR
55.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$126.3K
Annual income
$52,256.85
Full KRYAY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KRYAY vs ABBV

📍 KRYAY pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKRYAYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KRYAY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KRYAY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KRYAY
Annual income on $10K today (after 15% tax)
$143.70/yr
After 10yr DRIP, annual income (after tax)
$44,418.32/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KRYAY beats the other by $23,362.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KRYAY + ABBV for your $10,000?

KRYAY: 50%ABBV: 50%
100% ABBV50/50100% KRYAY
Portfolio after 10yr
$114.3K
Annual income
$38,514.31/yr
Blended yield
33.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KRYAY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.1
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KRYAY buys
0
ABBV buys
0
No recent congressional trades found for KRYAY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKRYAYABBV
Forward yield1.69%3.06%
Annual dividend / share$1.34$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR55.4%40.6%
Portfolio after 10y$126.3K$102.3K
Annual income after 10y$52,256.85$24,771.77
Total dividends collected$99.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: KRYAY vs ABBV ($10,000, DRIP)

YearKRYAY PortfolioKRYAY Income/yrABBV PortfolioABBV Income/yrGap
1$10,963$262.72$11,550$430.00$587.00ABBV
2$12,148$418.29$13,472$627.96$1.3KABBV
3$13,672$673.20$15,906$926.08$2.2KABBV
4$15,729$1,100.34$19,071$1,382.55$3.3KABBV
5$18,669$1,838.54$23,302$2,095.81$4.6KABBV
6$23,145$3,169.19$29,150$3,237.93$6.0KABBV
7$30,471$5,706.27$37,536$5,121.41$7.1KABBV
8$43,515$10,910.76$50,079$8,338.38$6.6KABBV
9$69,190$22,629.25$69,753$14,065.80$563.00ABBV
10← crossover$126,291$52,256.85$102,337$24,771.77+$24.0KKRYAY

KRYAY vs ABBV: Complete Analysis 2026

KRYAYStock

Kerry Group plc, together with its subsidiaries, develops, manufactures, and delivers taste and nutrition solutions for the food, beverage, and pharmaceutical industries in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company operates in two segments, Taste & Nutrition and Consumer Foods. The Taste & Nutrition segment provides taste, nutrition, and functional ingredients technologies and solutions for the food, beverage, and pharmaceutical markets. The Consumer Foods segment manufactures and supplies customer branded chilled food products primarily to the Irish and the United Kingdom markets. Kerry Group plc was founded in 1972 and is headquartered in Tralee, Ireland.

Full KRYAY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KRYAY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KRYAY vs SCHDKRYAY vs JEPIKRYAY vs OKRYAY vs KOKRYAY vs MAINKRYAY vs JNJKRYAY vs MRKKRYAY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.